Skip to main content
SpringerLink
Log in

Natural Course, Therapeutic Options and Economic Evaluation of Therapies for Chronic Hepatitis B

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Chronic hepatitis B virus infection afflicts 400 million people worldwide and untreated will progress to cirrhosis in 15–40% of individuals, with an associated increased risk for the development of hepatocellular carcinoma. The ‘inactive carrier state’ carries a benign prognosis with a very low risk of cirrhosis or hepatocellular carcinoma. However, the hepatitis B e antigen (HBeAg)-positive chronic hepatitis state is an active disease state with increased risk for progressing to cirrhosis and hepatocellular carcinoma. The HBeAg-negative mutant variety of chronic hepatitis B has been associated with a higher incidence of cirrhosis at initial presentation and more frequent progression to hepatocellular carcinoma compared with the wild-type hepatitis B.

Five medications are currently approved by the US FDA for the treatment of chronic hepatitis B: interferon-α, lamivudine, adefovir dipivoxil, entecavir and peginterferon-α-2a. Interferon-α therapy has been shown to increase the rate of HBeAg and hepatitis B DNA loss with a small chance of hepatitis B surface antigen loss, but has significant adverse effects and is ineffective against the HBeAg-negative mutant. Lamivudine is a safely used, orally administered drug with good efficacy, but is associated with the development of a lamivudine-resistant (Lam-R) mutant in a large proportion of patients after long-term therapy. High relapse rates after lamivudine therapy make this medication less effective in the HBeAg-negative mutant also. Adefovir dipivoxil is a safely used, orally administered drug, which is effective against the Lam-R mutant. Adefovir dipivoxil is effective against the wild-type and HBeAg-negative hepatitis B and has a very low incidence of resistance development. Entecavir is a highly potent and selective new oral drug against hepatitis B. It has demonstrated no resistance development in treatment-naive patients, but a low incidence of resistance in patients infected with prior Lam-R mutants. Peginterferon-α-2a is administered once weekly and has improved efficacy compared with standard interferon-α and lamivudine. However, it has a similar adverse-effect profile to standard interferon-α.

Pharmacoeconomic studies have demonstrated a cost benefit in treating chronic hepatitis B patients compared with no therapy. However, results have been conflicting, with earlier studies showing a cost advantage of lamivudine over interferon-α and a more recent, comprehensive study favouring interferon-α monotherapy in HBeAg-negative patients and adefovir dipivoxil ‘salvage’ after lamivudine resistance development in HBeAg-positive patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733–45

    Article  PubMed  CAS  Google Scholar 

  2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225–41

    Article  PubMed  CAS  Google Scholar 

  3. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000. Summary of a workshop. Gastroenterology 2001; 120: 1828–53

    CAS  Google Scholar 

  4. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362–6

    Article  PubMed  CAS  Google Scholar 

  5. Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am 1990 Nov; 74(6): 1529–41

    PubMed  CAS  Google Scholar 

  6. Milich DR, Chen MK, Hughes JL, et al. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160: 2013–21

    PubMed  CAS  Google Scholar 

  7. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522–7

    Article  PubMed  Google Scholar 

  8. de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118: 191–4

    PubMed  Google Scholar 

  9. Bortolotti F, Jara P, Crivellaro C, et al. Outcome of chronic hepatitis B in caucasian children during a 20-year observation period. J Hepatol 1998; 29: 184–90

    Article  PubMed  CAS  Google Scholar 

  10. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167–72

    Article  PubMed  CAS  Google Scholar 

  11. Hoofnagle JH, Dusheiko GM, Seeff LB, et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 744–8

    PubMed  CAS  Google Scholar 

  12. Realdi G, Alberti A, Rugge M, et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980; 79: 195–9

    PubMed  CAS  Google Scholar 

  13. Fong TL, Di Bisceglie AM, Gerber MA, et al. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993; 18: 1313–8

    Article  PubMed  CAS  Google Scholar 

  14. Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839–43

    PubMed  CAS  Google Scholar 

  15. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009–22

    Article  PubMed  CAS  Google Scholar 

  16. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257–64

    Article  PubMed  Google Scholar 

  17. Moreno-Otero R, Garcia-Monzon C, Garcia-Sanchez A, et al. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. Am J Gastroenterol 1991; 86: 560–4

    PubMed  CAS  Google Scholar 

  18. Zarski JP, Marcellin P, Cohard M, et al. Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group. J Hepatol 1994; 20: 636–40

    CAS  Google Scholar 

  19. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617–24

    Article  PubMed  CAS  Google Scholar 

  20. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; II: 588–91

    Article  Google Scholar 

  21. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 2001; 8: 311–21

    Article  PubMed  CAS  Google Scholar 

  22. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294–8

    Article  PubMed  CAS  Google Scholar 

  23. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: aprospective observation of 2215 patients. J Hepatol 1998; 28: 930–8

    Article  PubMed  CAS  Google Scholar 

  24. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493–6

    Article  PubMed  CAS  Google Scholar 

  25. Fattovich G, Brollo L, Alberti A, et al. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology 1988; 8: 1651–4

    Article  PubMed  CAS  Google Scholar 

  26. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886–95

    Article  PubMed  Google Scholar 

  27. Liaw YF, Lin DY, Chen TJ, et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9: 235–41

    Article  PubMed  CAS  Google Scholar 

  28. Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145: 1039–47

    Article  PubMed  CAS  Google Scholar 

  29. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32: 842–6

    Article  PubMed  CAS  Google Scholar 

  30. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study. Gastroenterology 1986; 90: 263–7

    PubMed  CAS  Google Scholar 

  31. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002 Jun; 83 (Pt 6): 1267–80

    PubMed  CAS  Google Scholar 

  32. Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998–1002

    Article  PubMed  CAS  Google Scholar 

  33. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756–62

    Article  PubMed  CAS  Google Scholar 

  34. RegenceRX. Pharmacy benefit management [online]. Available from URL: http://www.regencerx.com/learn/rxPriceGuide/index.html [Accessed 2006 Jul 4]

  35. Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005 Jun 30; 352(26): 2743–6

    Article  PubMed  CAS  Google Scholar 

  36. Rosen HR. Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury. Liver Transpl 2003 Nov; 9(11): S35–43

    Article  PubMed  Google Scholar 

  37. Wong DK, Cheung AM, O’Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312–23

    PubMed  CAS  Google Scholar 

  38. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971–5

    Article  PubMed  CAS  Google Scholar 

  39. Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139–45

    Article  PubMed  CAS  Google Scholar 

  40. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660–7

    Article  PubMed  CAS  Google Scholar 

  41. Fattovich G, Giustina G, Realdi G, et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26: 1338–42

    PubMed  CAS  Google Scholar 

  42. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422–7

    Article  PubMed  CAS  Google Scholar 

  43. Lok AS, Chung HT, Liu VW, et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833–8

    PubMed  CAS  Google Scholar 

  44. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761–3

    Article  PubMed  CAS  Google Scholar 

  45. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295–301

    CAS  Google Scholar 

  46. Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30: 238–43

    PubMed  CAS  Google Scholar 

  47. Carreno V, Marcellin P, Hadziyannis S, et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30: 277–82

    PubMed  CAS  Google Scholar 

  48. Brunetto MR, Oliveri F, Colombatto P, et al. Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. J Hepatol 1995; 22: 42–4

    PubMed  CAS  Google Scholar 

  49. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198–202

    Article  PubMed  CAS  Google Scholar 

  50. Hadziyannis S, Bramou T, Makris A, et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990; 11 Suppl. 1: S133–6

    Article  PubMed  Google Scholar 

  51. Pastore G, Santantonio T, Milella M, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992; 14: 221–5

    Article  PubMed  CAS  Google Scholar 

  52. Oliveri F, Santantonio T, Bellati G, et al. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999; 94: 1366–72

    PubMed  CAS  Google Scholar 

  53. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101–9

    Article  PubMed  CAS  Google Scholar 

  54. Lok AS. Hepatitis B infection: pathogenesis and management. J Hepatol 2000; 32: 89–97

    Article  PubMed  CAS  Google Scholar 

  55. Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B. Drugs 1999; 58: 101–41

    Article  PubMed  CAS  Google Scholar 

  56. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256–63

    Article  PubMed  CAS  Google Scholar 

  57. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61–8

    CAS  Google Scholar 

  58. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562–8

    Article  PubMed  CAS  Google Scholar 

  59. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172–80

    CAS  Google Scholar 

  60. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527–32

    Article  PubMed  CAS  Google Scholar 

  61. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186–94

    Article  PubMed  CAS  Google Scholar 

  62. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30: 770–4

    CAS  Google Scholar 

  63. Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078–88

    Article  PubMed  CAS  Google Scholar 

  64. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001; 12 Suppl. 1: 67–71

    PubMed  CAS  Google Scholar 

  65. Lewin SR, Ribeiro RM, Walters T, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001; 34: 1012–20

    Article  PubMed  CAS  Google Scholar 

  66. Liu CJ, Chen PJ, Lai MY, et al. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 2001; 34: 583–9

    Article  PubMed  CAS  Google Scholar 

  67. Bonacini M, Kurz A, Locarnini S, et al. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002; 122: 244–5

    Article  PubMed  Google Scholar 

  68. Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31: 1318–26

    Article  PubMed  CAS  Google Scholar 

  69. Kim JW, Lee HS, Woo GH, et al. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001; 33: 403–5

    Article  PubMed  CAS  Google Scholar 

  70. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847–51

    Article  PubMed  CAS  Google Scholar 

  71. Papatheodoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219–26

    Article  PubMed  Google Scholar 

  72. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300–6

    Article  PubMed  CAS  Google Scholar 

  73. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889–96

    Article  PubMed  CAS  Google Scholar 

  74. Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145–53

    Article  PubMed  CAS  Google Scholar 

  75. Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003; 9: 49–56

    Article  PubMed  Google Scholar 

  76. Fontana RJ, Hann HW, Wright T, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7: 504–10

    Article  PubMed  CAS  Google Scholar 

  77. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808–16

    Article  PubMed  CAS  Google Scholar 

  78. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800–7

    Article  PubMed  CAS  Google Scholar 

  79. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292–7

    Article  PubMed  Google Scholar 

  80. Walsh KM, Woodall T, Lamy P, et al. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49: 436–40

    Article  PubMed  CAS  Google Scholar 

  81. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129–34

    Article  PubMed  CAS  Google Scholar 

  82. Xiong X, Flores C, Yang H, et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669–73

    Article  PubMed  CAS  Google Scholar 

  83. Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 1912–4

    Article  PubMed  CAS  Google Scholar 

  84. Westland CE, Yang H, Delaney WE, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38: 96–103

    Article  PubMed  CAS  Google Scholar 

  85. Yang H, Westland CE, Delaney WE, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464–73

    Article  PubMed  CAS  Google Scholar 

  86. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673–81

    Article  PubMed  CAS  Google Scholar 

  87. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419–27

    PubMed  CAS  Google Scholar 

  88. Chang T, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatits B: results of phase III study ETV-022 in nucleoside-naive patients [abstract no. 70]. Hepatology 2004; 40 (4 Suppl. 1): 193A

    Google Scholar 

  89. Shouval D, Lai C-L, Cheinquer H, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(−) chronic hepatitis B: results of phase III trial ETV-027 [abstract no. LB07]. Hepatology 2004; 40 (4 Suppl. 1): 728A

    Google Scholar 

  90. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-re-fractory, HBeAg(+) chronic hepatitis B: results of phase III study ETV-026 [abstract no. 1152]. Hepatology 2006; 40 (4 Suppl. 1): 664A

    Google Scholar 

  91. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298–305

    Article  PubMed  CAS  Google Scholar 

  92. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–95

    Article  PubMed  CAS  Google Scholar 

  93. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206–17

    Article  PubMed  CAS  Google Scholar 

  94. Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B: an Italian multicenter, randomized trial. J Hepatol 2001; 35: 406–11

    Article  PubMed  CAS  Google Scholar 

  95. Yalcin K, Degertekin H, Yildiz F, et al. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003; 36: 1516–22

    Article  PubMed  CAS  Google Scholar 

  96. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81–90

    Article  PubMed  CAS  Google Scholar 

  97. Peters MG, Hann HH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91–101

    Article  PubMed  CAS  Google Scholar 

  98. Brook MG, Petrovic L, McDonald JA, et al. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection. J Hepatol 1989; 8: 218–25

    Article  PubMed  CAS  Google Scholar 

  99. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen serocon-version after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803–6

    Article  PubMed  CAS  Google Scholar 

  100. Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743–8

    Article  PubMed  CAS  Google Scholar 

  101. Data on file, Study 481, Gilead Sciences

  102. Bootman JL, Townsend RJ, McGhan WF. Introduction to pharmacoeconomics. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of pharmacoeconomics. 2nd ed. Cincinnati (OH): Harvey Whitney Books, 1996: 4–20

    Google Scholar 

  103. Torrance GW, Siegel JE, Luce BR. Framing and designing the cost-effectiveness analysis. In: Gold MR, Siegel JA, Russell LB, editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996: 54–80

    Google Scholar 

  104. Wong JB, Koff RS, Tine F, et al. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664–75

    PubMed  CAS  Google Scholar 

  105. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22: 1863–73

    PubMed  CAS  Google Scholar 

  106. Brooks EA, Lacey LF, Payne SL, et al. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Am J Manag Care 2001; 7: 677–82

    PubMed  CAS  Google Scholar 

  107. Crowley SJ, Tognarini D, Desmond PV, et al. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17: 409–27

    Article  PubMed  CAS  Google Scholar 

  108. Crowley S, Tognarini D, Desmond P, et al. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002; 17: 153–64

    Article  PubMed  CAS  Google Scholar 

  109. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142: 821–31

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The author received grants and honoraria and acted as a consultant to Roche, Gilead and Bristol-Myers Squibb.

Author information

Authors and Affiliations

  1. David Geffen School of Medicine at UCLA, Pfleger Liver Institute, 200 Medical Plaza, Suite 214, Los Angeles, California, 90095-7302, USA

    Steven-Huy B. Han

Authors
  1. Steven-Huy B. Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven-Huy B. Han.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, SH.B. Natural Course, Therapeutic Options and Economic Evaluation of Therapies for Chronic Hepatitis B. Drugs 66, 1831–1851 (2006). https://doi.org/10.2165/00003495-200666140-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666140-00005

Keywords

Search

Navigation